A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)

Recruiting now · Phase 1

Conditions studied: Metastatic Castration-resistant Prostate Cancer

In brief

This study will assess the safety and tolerability of valemetostat in combination with darolutamide in participants with Metastatic Castration Resistant Prostate Cancer (mCRPC).

Key facts

Study ID
NCT07244341
Run by
Daiichi Sankyo
People needed
60
Starts
2025-12-03
Expected to finish
2029-11-30
Last updated by the study team
2026-05-15

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.